CIK 0001520262 · Large accelerated filer
Alkermes plc.
Sign in to watch- Ticker
- ALKS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 981007018
- Phone
- 00-353-1-772-8000
- Business address
- CONNAUGHT HOUSE, 1 BURLINGTON ROAD, DUBLIN 4, Ireland, 00000
- Former names
- ANTLER SCIENCE TWO PLC, Antler Science Two Ltd
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,070,874
- in 5 filings, $1.1M under 10b5-1 plans
Net −$1,070,874. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-18 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | Option exercise · Restricted Stock Unit Award | −6,354 | 6,355 | ||
| 2025-02-18 | Brown Iain Michael SVP, Chief Financial Officer | Option exercise | +6,354 | 139,749 | ||
| 2025-02-18 | Brown Iain Michael SVP, Chief Financial Officer | Shares withheld for taxes | −1,869 | $35.90 | $67K | 137,880 |
| 2025-02-18 | Brown Iain Michael SVP, Chief Financial Officer | Option exercise · Restricted Stock Unit Award | −6,354 | 6,355 | ||
| 2025-02-18 | Jackson Blair Curtis EVP, Chief Operating Officer | Option exercise | +8,896 | 190,444 | ||
| 2025-02-18 | Jackson Blair Curtis EVP, Chief Operating Officer | Shares withheld for taxes | −3,950 | $35.90 | $142K | 186,494 |
| 2025-02-18 | Jackson Blair Curtis EVP, Chief Operating Officer | Option exercise · Restricted Stock Unit Award | −8,896 | 8,897 | ||
| 2025-02-18 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise | +8,896 | 66,771 | ||
| 2025-02-18 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Shares withheld for taxes | −3,950 | $35.90 | $142K | 62,821 |
| 2025-02-18 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise · Restricted Stock Unit Award | −8,896 | 8,897 | ||
| 2025-02-13 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise 10b5-1 | +108,833 | $31.93 | $3.5M | 166,708 |
| 2025-02-13 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise 10b5-1 | +35,586 | $24.59 | $875K | 202,294 |
| 2025-02-13 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Sale 10b5-1 | −35,586 | $34.02 | $1.2M | 166,708 |
| 2025-02-13 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Sale 10b5-1 | −108,833 | $36.02 | $3.9M | 57,875 |
| 2025-02-13 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise · Employee Stock Option (Right to Buy) 10b5-1 | −108,833 | 0 | ||
| 2025-02-13 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise · Employee Stock Option (Right to Buy) 10b5-1 | −35,586 | 71,172 | ||
| 2025-02-12 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise 10b5-1 | +87,566 | $20.03 | $1.8M | 151,166 |
| 2025-02-12 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise 10b5-1 | +111,630 | $19.34 | $2.2M | 262,796 |
| 2025-02-12 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Sale 10b5-1 | −171,813 | $32.69 | $5.6M | 90,983 |
| 2025-02-12 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Sale 10b5-1 | −33,108 | $33.27 | $1.1M | 57,875 |
Page 18 of 41 · 804 trades